Wellell Biotech Announces 2025 Q4 Earnings: EPS of NT$2.96
Wellell Biotech Co., Ltd. (stock code 1783) reported its financial results for the fourth quarter of 2025. The company posted an earnings per share (EPS) of NT$2.96 for the quarter. Revenue reached NT$812 million, with a net profit after tax of NT$265 million. Wellell Biotech operates in the biotechnology and medical industry, focusing on collagen and hyaluronic acid.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Company Code: 1783
Company Name: Wellell Biotech Co., Ltd.
Industry: Biotechnology and Medical
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$2.96
Operating Revenue: NT$812 million
Net Profit After Tax: NT$265 million
Company Name: Wellell Biotech Co., Ltd.
Industry: Biotechnology and Medical
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$2.96
Operating Revenue: NT$812 million
Net Profit After Tax: NT$265 million
FAQ
What was Wellell Biotech's revenue in Q4 2025?
Wellell Biotech's operating revenue for Q4 2025 was NT$812 million.
What was Wellell Biotech's net profit in Q4 2025?
The net profit after tax for Wellell Biotech in Q4 2025 was NT$265 million.
What is Wellell Biotech's stock code?
Wellell Biotech's stock code is 1783.